BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised persons. Hum Vaccin Immunother 2018;14:1311-22. [PMID: 29485353 DOI: 10.1080/21645515.2018.1445446] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Buchy P, Badur S. Who and when to vaccinate against influenza. International Journal of Infectious Diseases 2020;93:375-87. [DOI: 10.1016/j.ijid.2020.02.040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
2 Papadopoli R, De Sarro C, Palleria C, Gallelli L, Pileggi C, De Sarro G. Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population. Vaccines (Basel) 2021;9:1494. [PMID: 34960240 DOI: 10.3390/vaccines9121494] [Reference Citation Analysis]
3 Allen JD, Ross TM. Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses. Sci Rep 2021;11:4554. [PMID: 33654128 DOI: 10.1038/s41598-020-79590-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Haddiya I. Current Knowledge of Vaccinations in Chronic Kidney Disease Patients. Int J Nephrol Renovasc Dis 2020;13:179-85. [PMID: 32801834 DOI: 10.2147/IJNRD.S231142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sgrulletti M, Ottaviano G, Sangerardi M, Chini L, Dellepiane RM, Martire B, Montin D, Rizzo C, Moschese V. One step closer to influenza vaccine inclusiveness. Pediatr Allergy Immunol 2020;31 Suppl 26:69-71. [PMID: 33236432 DOI: 10.1111/pai.13338] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Chen J, Wang J, Zhang J, Ly H. Advances in Development and Application of Influenza Vaccines. Front Immunol 2021;12:711997. [PMID: 34326849 DOI: 10.3389/fimmu.2021.711997] [Reference Citation Analysis]
7 Zhou X, Liu Y, Jin Y, Wang Y, Miao M, Chen J, Cheng Y, Liu Y, He J, Li Z. Immune responses after influenza vaccination in patients of primary Sjögren's syndrome. Rheumatology (Oxford) 2021;60:224-30. [PMID: 32671409 DOI: 10.1093/rheumatology/keaa243] [Reference Citation Analysis]
8 Bianchi FP, Rizzo LA, De Nitto S, Stefanizzi P, Tafuri S. Influenza vaccination coverage among splenectomized patients: an Italian study on the role of active recall in the vaccination compliance. Hum Vaccin Immunother 2019;15:2644-9. [PMID: 31063019 DOI: 10.1080/21645515.2019.1599678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Rosamilia F, Noberasco G, Olobardi D, Orsi A, Icardi G, Lantieri F, Murdaca G. Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review. Vaccines (Basel) 2021;9:1330. [PMID: 34835261 DOI: 10.3390/vaccines9111330] [Reference Citation Analysis]
10 Rivera-Izquierdo M, Valero-Ubierna MDC, Nieto-Gómez P, Martínez-Bellón MD, Fernández-Martínez NF, Barranco-Quintana JL. Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. Expert Rev Vaccines 2020;19:727-44. [PMID: 32702246 DOI: 10.1080/14760584.2020.1800462] [Reference Citation Analysis]
11 Babu TM, Kotton CN. Immunizations in Chronic Kidney Disease and Kidney Transplantation. Curr Treat Options Infect Dis 2021;:1-19. [PMID: 34025219 DOI: 10.1007/s40506-021-00248-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sethi S, Kumar A, Mandal A, Shaikh M, Hall CA, Kirk JMW, Moss P, Brookes MJ, Basu S. The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy. BMJ Open 2021;11:e048856. [PMID: 34130964 DOI: 10.1136/bmjopen-2021-048856] [Reference Citation Analysis]
13 Pan Y, Du L, Gan Q, Ma W, Wang M, Lu Z, Luo Y. Meta-analysis of whether influenza vaccination attenuates symptom severity in vaccinated influenza patients. Public Health Nurs 2021. [PMID: 34614241 DOI: 10.1111/phn.12985] [Reference Citation Analysis]
14 Chang YT, Ling TC, Cheng YY, Sun CY, Wu JL, Tai CH, Wang JR, Sung JM. Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial. Vaccines (Basel) 2021;9:192. [PMID: 33669067 DOI: 10.3390/vaccines9030192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lin CH, Chen CH, Hong SY, Lin SS, Chou IC, Lin HC, Chang JS. Comparison of severe pediatric complicated influenza patients with and without neurological involvement. Medicine (Baltimore) 2021;100:e25716. [PMID: 33907160 DOI: 10.1097/MD.0000000000025716] [Reference Citation Analysis]
16 Ferenci T, Sarkadi B. RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07069-z] [Reference Citation Analysis]
17 Cataldi JR, Hurley LP, Lindley MC, O'Leary ST, Gorman C, Brtnikova M, Beaty BL, Crane LA, Shay DK, Kempe A. Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians. J Gen Intern Med 2021;36:2030-8. [PMID: 33483822 DOI: 10.1007/s11606-020-06397-7] [Reference Citation Analysis]
18 Li Y, Wang LL, Xie LL, Hou WL, Liu XY, Yin S. The epidemiological and clinical characteristics of the hospital-acquired influenza infections: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25142. [PMID: 33725996 DOI: 10.1097/MD.0000000000025142] [Reference Citation Analysis]
19 Roubidoux EK, Schultz-Cherry S. Animal Models Utilized for the Development of Influenza Virus Vaccines. Vaccines (Basel) 2021;9:787. [PMID: 34358203 DOI: 10.3390/vaccines9070787] [Reference Citation Analysis]
20 Lai JJ, Lin C, Ho CL, Chen PH, Lee CH. Alternative-Dose versus Standard-Dose Trivalent Influenza Vaccines for Immunocompromised Patients: A Meta-Analysis of Randomised Control Trials. J Clin Med 2019;8:E590. [PMID: 31035712 DOI: 10.3390/jcm8050590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Karacin C, Eren T, Zeynelgil E, Imamoglu GI, Altinbas M, Karadag I, Basal FB, Bilgetekin I, Sutcuoglu O, Yazici O, Ozdemir N, Ozet A, Yildiz Y, Esen SA, Ucar G, Uncu D, Dinc B, Aykan MB, Erturk İ, Karadurmus N, Civelek B, Çelik İ, Ergun Y, Dogan M, Oksuzoglu OB. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncol 2021. [PMID: 34342517 DOI: 10.2217/fon-2021-0597] [Reference Citation Analysis]
22 Yoon Y, Choi JS, Park M, Cho H, Park M, Huh HJ, Kim YJ, Son MH. Influenza Vaccine Effectiveness in Children at the Emergency Department during the 2018-2019 Season: the First Season School-aged Children Were Included in the Korean Influenza National Immunization Program. J Korean Med Sci 2021;36:e71. [PMID: 33724738 DOI: 10.3346/jkms.2021.36.e71] [Reference Citation Analysis]
23 Checkmahomed L, Padey B, Pizzorno A, Terrier O, Rosa-Calatrava M, Abed Y, Baz M, Boivin G. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Viruses 2020;12:E1139. [PMID: 33049959 DOI: 10.3390/v12101139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Marathe BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, Jones J, Webby RJ, Krammer F, Govorkova EA. Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. Antimicrob Agents Chemother 2020;64:e00284-20. [PMID: 32631823 DOI: 10.1128/AAC.00284-20] [Reference Citation Analysis]
25 Noé A, Cargill TN, Nielsen CM, Russell AJC, Barnes E. The Application of Single-Cell RNA Sequencing in Vaccinology. J Immunol Res 2020;2020:8624963. [PMID: 32802896 DOI: 10.1155/2020/8624963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Colmegna I, Useche ML, Rodriguez K, Mccormack D, Alfonso G, Patel A, Ramanakumar AV, Rahme E, Bernatsky S, Hudson M, Ward BJ. Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial. The Lancet Rheumatology 2020;2:e14-23. [DOI: 10.1016/s2665-9913(19)30094-3] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
27 Patel M, Chen J, Kim S, Garg S, Flannery B, Haddadin Z, Rankin D, Halasa N, Talbot HK, Reed C. Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States. Emerg Infect Dis 2020;26:1720-30. [PMID: 32348234 DOI: 10.3201/eid2608.191493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
28 Ginda T, Taradaj K, Kociszewska-najman B. The influence of selected factors on the immunogenicity of preventive vaccinations against hepatitis A, B and influenza in solid organ transplant recipients undergoing immunosuppressive therapy – a review. Expert Review of Vaccines. [DOI: 10.1080/14760584.2022.2027241] [Reference Citation Analysis]
29 Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, Reimann P, Lang T, Atzl M, Huynh M, Gasser K, Petrausch U, Fraunberger P, Hartmann B, Winder T. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. Br J Haematol 2021. [PMID: 34346068 DOI: 10.1111/bjh.17743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Friedmann D, Goldacker S, Peter HH, Warnatz K. Preserved Cellular Immunity Upon Influenza Vaccination in Most Patients with Common Variable Immunodeficiency. J Allergy Clin Immunol Pract. 2020;8:2332-2340.e5. [PMID: 32330665 DOI: 10.1016/j.jaip.2020.04.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Scanlon N, Saklawi Y, Rouphael N. The Role of Systems Vaccinology in Understanding the Immune Defects to Vaccination in Solid Organ Transplant Recipients. Front Immunol 2020;11:582201. [PMID: 33324400 DOI: 10.3389/fimmu.2020.582201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Fukao K, Ando Y, Noshi T, Kitano M, Noda T, Kawai M, Yoshida R, Sato A, Shishido T, Naito A. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS One 2019;14:e0217307. [PMID: 31107922 DOI: 10.1371/journal.pone.0217307] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]